

Delete this line, then print on Trust/Hospital headed paper



CANCER
RESEARCH
UK



LEEDS
CLINICAL TRIALS UNIT



Personalising treatment for myeloma patients based on how well they initially respond to a period of NHS treatment and their overall fitness level

Randomised study treatment

We would like to invite you to **continue to take part in iFIT and receive further treatment**

*For NHS site reference: **iFIT3** (MRD-) – DR until PD / DR for 18 cycles*

Thank you for taking part in iFIT so far. You have now completed 6 cycles of the NHS treatment DRd.

This information explains the further treatment you could receive, based on your recent tests. The tests show that you do not have current detectable cancer cells in your bone marrow (MRD negative).

We will test if people need to continue daratumumab and lenalidomide treatment long-term, or whether the treatment can be stopped after a period without the myeloma returning any quicker.

It is completely up to you whether you continue to take part in this research. Your usual care won't be affected if you decide not to continue.

There are some different risks in continuing to take part in the research, compared with your usual care. Discuss the possible risks with your hospital doctor.

If you agree to take part, you can change your mind at any time and stop all or some parts of the research. If you want to change your level of involvement, just let your hospital doctor or nurse know.

How will we use information about you?

In this research study we will use information from you and your medical records. We will only use information that we need for the research study. We will let very few people know your name or contact details, and only if they really need it for this study.

Everyone involved in this study will keep your data safe and secure. We will also follow all privacy rules.

At the end of the study we will save some of the data in case we need to check it and for future research.

We will make sure no-one can work out who you are from the reports we write.

The information pack tells you more about this (See **Appendix 1** in the ‘**Study Registration**’ document).

To help you understand the research, the information is split into several documents:

iFIT document	This document	When will I receive this?	What is being asked of me?
Bone marrow sharing		When having tests to find out if you have myeloma	Do you agree to share a sample of your bone marrow from your planned tests?
Study registration		If you are diagnosed with myeloma	Do you agree to be monitored whilst having the NHS treatment DRd, and for us to collect your data and samples?
Randomised study treatment	✓	After completing a period of the NHS treatment DRd	Do you agree to continue to take part in the research and be randomly allocated to a further treatment based on your data?
Additional information [optional - you don't have to read this before you make your decision]		At the same time as the ‘Study registration’ document above	Nothing is being asked of you here. This is additional information you may find interesting or helpful.

Large-print and electronic versions of all documents are available. Visit <https://ctru.leeds.ac.uk/ifit>.

Ask your hospital doctor or nurse if you need another paper copy of the '**Study registration**' or '**Additional information**' documents. You were given a copy of these when you joined the research. These contain information that is still applicable to you now.

Please look through all the information in this '**Randomised study treatment**' document before you decide whether you would like to continue. There is space on page 10 of this document to add questions or notes.

We may update this information during the research. For example, if we learn something new about the treatments. We will tell you about any important updates and give you the chance to choose if you still want to take part or not.

Once you have read the information, your hospital doctor or nurse will talk to you about the research again and you can ask any questions you like.

Contents page

Who can I contact if I have more questions? 5

Can I receive any of the other further treatments?..... 5

If I want to, will I definitely be able to continue to take part? 5

What further treatment could I receive? 5

What else will happen? 6

Why will I not receive dexamethasone?..... 8

Why are you investigating stopping daratumumab and lenalidomide treatment? 8

What are the possible benefits of continuing to take part? 8

What are the potential risks and unwanted effects of daratumumab and lenalidomide?9

Any questions? 10

Who can I contact if I have more questions?

If you have any questions about this research, please talk to your <<enter Consultant, Doctor, Nurse, Researcher>>:

<< Enter name >>

<< Enter contact details >>

Can I receive any of the other further treatments?

Unfortunately, no. You are only able to receive one of the further treatments described in this document. These further treatments are based on your response to the NHS treatment DRd, regardless of your level of fitness. Neither you nor your hospital doctor can change this.

You do not have to continue to take part in this research if you do not want to.

If I want to, will I definitely be able to continue to take part?

Unfortunately, no. Although you will be allocated one of these further treatments based on your initial response, your hospital doctor will still need to carry out some tests and ask you some questions. They need to make sure you are suitable and that it is safe for you to take part. You may have had some of these tests already and may not need to have them again.

These tests include blood tests, urine tests, bone marrow samples, imaging scans, and pregnancy tests (if you are female and are able to have children).

If your hospital doctor decides the research is not suitable for you, or if you decide not to take part, your hospital doctor will discuss your alternative treatment options with you.

What further treatment could I receive?

If you decide to continue to take part in this research, your hospital doctor will not decide what treatment you get out of the options listed here. Instead, you would get one of the treatments by chance (randomly).

This means if you agree to continue to take part, you will have an equal chance of getting either of the treatments. You should only agree to continue to take part if you are happy with this.

We do this so that we can do a fair test of which treatment is best. We only do this because we do not know which of the treatments is best.

This process is called 'randomisation', and you will be randomised to **continue Daratumumab and lenalidomide** (also known as **Revlimid®**) for:

1. As long as your myeloma remains under control. This could be a few months or several years.

OR

2. For 18 further cycles. After 18 cycles you will stop the treatment and you will continue to be closely monitored by your hospital doctor around every 28 days.

You will continue your treatment as you have been. However, the daratumumab **injection** will be reduced to once a month (on day 1 of each 28-day cycle), and you will no longer take dexamethasone.

Before the start of each cycle of treatment, your hospital doctor will carry out some tests (including a blood test) to make sure it is safe and suitable for you to continue receiving treatment. This will also happen when you are not receiving treatment but are still being closely monitored by your hospital doctor, to see how you are doing.

You will continue to receive the treatment as planned, if the tests show you are tolerating the treatment, and your myeloma remains under control.

Other treatments are available. Talk to your hospital doctor about this.

You will be given some additional medications to help combat the possible side effects of these myeloma treatments. Your hospital doctor will decide exactly which treatments you need for this.

Occasionally on receiving new information, your hospital doctor may consider it be in your best interest that you stop taking any further study treatment.

What else will happen?

- **Blood and bone marrow samples**

We will collect samples of your blood and bone marrow aspirate (fluid) at the following times:

- After 6 cycles of treatment (blood only),
- After 18 cycles of treatment,
- After 30 cycles of treatment, or 12 28-day periods of continuing to be closely monitored by your hospital doctor after treatment, and
- If you are no longer responding to treatment.

We will take up to an additional 4 teaspoons (20mL) of blood and 2 teaspoons (10mL) of bone marrow aspirate (fluid) each time.

It is expected that most of the blood samples will be taken at the same time as your routine hospital tests. These should not require any additional needle punctures.

You would likely have a bone marrow sample taken if you are no longer responding to treatment, even if you were not taking part in this research. However, the extra bone marrow samples for this research allow us to see how well you are responding to the treatment. Parts of the samples will also be used in laboratory research to understand who responds best to which treatments.

- **Questionnaires**

We will ask you to complete a total of 6 further sets of questionnaires. This will be at 3, 6, 12, 18, 24 and 30 months from randomisation (when you are allocated by chance to a further treatment). If you stop treatment or being closely monitored by your hospital doctor, we will still ask you to complete these around the time they would have been due.

This is to help us determine the impact of this research on your emotional and physical wellbeing, and how you have used healthcare services. The questionnaires are confidential. Your hospital doctor or nurse will not see what you have written.

You may continue to complete the questionnaires on paper, or you may now change to completing the questionnaires online.

If you choose to complete the questionnaires online, we will collect your email address and/or mobile number, and you will be sent a link to complete by the method you prefer. You will receive up to 3 reminders to complete each questionnaire.

Please let your hospital doctor or nurse know if you change your email address or phone number during the research. Otherwise, we might not be able to send questionnaires to you in this way.

A guide to completing your questionnaires using the online method is provided in the '**Additional information**' document.

- **Data collection**

We will collect further data about you and your health.

Your hospital doctor will look at some information about you, and if you have any other illnesses. They will also ask you some questions about your lifestyle. This is a way of determining your level of fitness. This will happen after every 6 cycles of treatment or period of being closely monitored by your hospital doctor, for a maximum of 6 times.

Why will I not receive dexamethasone?

Dexamethasone is associated with some unpleasant side effects, particularly for people with myeloma with a lower level of fitness.

We do not believe that you need to carry on taking dexamethasone because you have no current detectable cancer cells in your bone marrow.

Why are you investigating stopping daratumumab and lenalidomide treatment?

People with myeloma who do not have current detectable cancer cells in their bone marrow after the NHS treatment DRd often have great longer-term outcomes.

For this reason, it is not certain whether these people need to stay on treatment indefinitely.

We will test if people need to continue daratumumab and lenalidomide long-term, or whether it can be stopped after a period without the myeloma returning any quicker. We do not know whether stopping the daratumumab and lenalidomide will make your myeloma come back sooner.

If you stop daratumumab and lenalidomide and your myeloma returns, your hospital doctor will discuss additional treatment with you in line with your usual care.

What are the possible benefits of continuing to take part?

People with myeloma often wish to know if they can have a treatment break after a fixed amount of time, without making the myeloma come back more quickly.

By continuing to take part, you will help us answer this important question, even if you are not randomised to stop treatment.

We are doing this research because we do not know whether it is best to stop daratumumab and lenalidomide after 18 further treatment cycles, or not. We want to find out which is best at the end of the research. It might be that the option you get in the research is better, but we won't know until the end of the research.

What are the potential risks and unwanted effects of daratumumab and lenalidomide?

Refer to the '**Study registration**' document for risks and side effects associated with daratumumab and lenalidomide, as well as other information we want to make you aware of. Talk to your hospital doctor or nurse if you need another copy of the '**Study registration**' document.

As you will receive only daratumumab and lenalidomide, the dexamethasone side effects will not be applicable to you.

Any questions?

You can use this space to write down any questions/notes you have about the research. You can then share them with your hospital doctor or nurse.

[illegible]

Delete this line, then print on Trust/Hospital headed paper



CANCER
RESEARCH
UK



LEEDS
CLINICAL TRIALS UNIT



Participant ID:	Initials:
Date of Birth:	NHS number (or CHI number for Scotland):
ISRCTN:	Principal Investigator:

PARTICIPANT INFORMED CONSENT DOCUMENT FOR RANDOMISATION (iFIT3)

*Please
initial for
each
statement*

1. I confirm that I have read through this randomised study information document and have had the opportunity to ask questions.

Initials

2. I agree to a copy of this Consent Form being securely sent to the Leeds Clinical Trials Research Unit. I understand that this will show my name and signature.

Initials

3. I agree to continue my participation in the research and receive one of the further treatments by chance (randomly).

Initials

Patient (to be completed by the patient):

Signature.....

Name (block capitals).....

Date.....

Investigator:

I have explained the research to the above-named patient and they have indicated their willingness to participate.

Signature.....

Name (block capitals).....

Date.....

Witness:

I have completed this consent form on behalf of the person named above who has freely given their consent to participate.

Signature.....

Name (block capitals).....

Date.....

(1 copy for patient; 1 for the CTRU; 1 held in patient notes; original stored in Investigator Site File)